NLM Digital Collections

Search

Start Over Subjects Economics, Pharmaceutical ✖Remove constraint Subjects: Economics, Pharmaceutical

2. Snapshots of recent state initiatives in Medicaid prescription drug cost control

Author(s):
Young, Katherine, author
Garfield, Rachel, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Cost Control -- statistics & numerical data
Cost Control -- trends
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicaid -- trends
Disclosure
Drugs, Generic -- economics
Economics, Pharmaceutical
Federal Government
Forecasting
Formularies as Topic
State Government
Humans
United States
United States. Food and Drug Administration.

3. Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers

Author(s):
Doshi, Jalpa A., author
Puckett, Justin T., author
Parmacek, Michael S., author
Rader, Daniel J., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Eligibility Determination
Insurance Coverage
Insurance, Health
Proprotein Convertase 9 -- antagonists & inhibitors
Serine Proteinase Inhibitors -- economics
Serine Proteinase Inhibitors -- therapeutic use
Economics, Pharmaceutical
Formularies as Topic
Hypercholesterolemia -- drug therapy
Medicaid -- economics
Medicare -- economics
Private Sector
Public Sector
Humans
Pennsylvania
United States

5. Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit

Author(s):
Pearson, Steven D., author
Dreitlein, Bill, author
Henshall, Chris, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Drug Costs
Economics, Pharmaceutical
Insurance, Pharmaceutical Services -- economics
Prospective Payment System
Reimbursement Mechanisms -- economics
Cost Savings
Cost Sharing
Formularies
Medicaid -- economics
Medicare -- economics
Off-Label Use -- economics
Pilot Projects
Value-Based Purchasing
Humans
United States

6. The prescription drug safety net: access to pharmaceuticals for the uninsured

Publication:
Washington, D.C. : George Washington University, [2007]
Subject(s):
Health Services Accessibility
Medical Assistance
Pharmaceutical Services
Uncompensated Care
Adult
Charities
Drug Industry
Drug Prescriptions -- economics
Economics, Pharmaceutical
Government Programs
HIV Infections -- drug therapy
Insurance, Pharmaceutical Services -- statistics & numerical data
Medically Uninsured
Middle Aged
Physician's Role
Practice Patterns, Physicians'
Humans
United States
United States. Health Resources and Services Administration.

7. Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, July 18, 2017
Subject(s):
Government Regulation
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Contract Services
Economics, Pharmaceutical
Forecasting
Government Programs -- statistics & numerical data
Insurance, Health, Reimbursement
Pharmacies -- statistics & numerical data
Pharmacies -- trends
Humans
United States
United States. Health Resources and Services Administration.

9. Survey brief: drug companies reduce patients’ access to care by limiting 340B community pharmacies

Publication:
[Washington, D.C.] : American Hospital Association, November 2022
Subject(s):
Community Pharmacy Services -- legislation & jurisprudence
Drug Costs -- legislation & jurisprudence
Drug Industry -- legislation & jurisprudence
Economics, Pharmaceutical
Health Services Accessibility
United States
340B Drug Pricing Program (U.S.)

14. The role of clinical and cost information in Medicaid pharmacy benefit decisions: experience in seven states

Author(s):
Gaffney, Jenny, author
Kress, Marielle, author
Pearson, Caroline, author
Carino, Tanisha, author
Connolly, John, author
Rudowitz, Robin, author
Publication:
Washington, DC : Henry J. Kaiser Family Foundation, September 2011
Subject(s):
Economics, Pharmaceutical
Insurance, Pharmaceutical Services
Medicaid -- economics
Pharmaceutical Preparations -- economics
State Health Plans -- economics
United States

16. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

18. Cost savings

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Cost Control -- legislation & jurisprudence
Cost Savings
Drug Costs -- legislation & jurisprudence
Economics, Pharmaceutical
Legislation, Drug
Access to Information
Biosimilar Pharmaceuticals
Commerce
Conflict of Interest
Drug Industry
Insurance, Pharmaceutical Services
Managed Care Programs
Medicaid -- economics
Medicare Part D -- economics
Patents as Topic
State Government
Humans
United States

19. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

20. Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, October 2019
Subject(s):
Drug Approval -- economics
Drug Approval -- legislation & jurisprudence
Investigational New Drug Application -- legislation & jurisprudence
Diffusion of Innovation
Economics, Pharmaceutical
Orphan Drug Production -- economics
Public Health
Small Business
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.